Skip to main content

Compare Stocks

Date Range: 

 Peak PharmaceuticalsWillistonTower One WirelessAcura PharmaceuticalsBetterLife Pharma
SymbolOTCMKTS:PKPHOTCMKTS:WHCAOTCMKTS:TOWTFOTCMKTS:ACUROTCMKTS:BETRF
Price Information
Current Price$0.11$0.70$0.10$0.38$0.49
52 Week RangeN/AN/AN/AN/AN/A
MarketRank™
Overall Score0.70.00.00.60.0
Analysis Score0.00.00.00.00.0
Community Score3.70.00.02.80.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market Cap$8.51 million$9.51 million$9.33 million$8.40 million$8.46 million
Beta0.46-1.090.20.793.8
Average Volume370,884720113,58215,53577,276
Sales & Book Value
Annual RevenueN/AN/A$4.08 million$2.66 millionN/A
Price / SalesN/AN/A2.293.16N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/AN/A($0.07) per share($0.22) per share$0.12 per share
Price / BookN/AN/A-1.43-1.73N/A
Profitability
Net IncomeN/AN/A$-3,750,000.00N/A$-14,780,000.00
EPSN/AN/AN/AN/AN/A
Trailing P/E Ratio0.000.00N/AN/AN/A
Forward P/E Ratio
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-19.89%N/A
Return on Equity (ROE)N/AN/AN/A-1.36%-734.15%
Return on Assets (ROA)N/AN/A-39.36%-34.83%-219.66%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current RatioN/AN/A0.08%1.37%0.16%
Quick RatioN/AN/A0.08%1.37%0.16%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/A5.60%34.77%
Miscellaneous
Employees1N/AN/A127
Shares Outstanding78.36 million13.58 million93.34 million22.11 million17.21 million
Next Earnings DateN/AN/A7/13/2021 (Estimated)7/5/2021 (Estimated)7/5/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
BetterLife Pharma files patent protection for an implant designed to mitigate excess psychedelic dosage effectsBetterLife Pharma files patent protection for an implant designed to mitigate excess psychedelic dosage effects
proactiveinvestors.com - May 1 at 10:07 AM
BetterLife files patent for implant to prevent drug diversion of LSD and other psychedelic drugsBetterLife files patent for implant to prevent drug diversion of LSD and other psychedelic drugs
canadianinvestor.com - April 29 at 3:31 PM
BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent Drug Diversion of LSD and Other Psychedelic DrugsBetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent Drug Diversion of LSD and Other Psychedelic Drugs
finance.yahoo.com - April 29 at 10:31 AM
April Psychedelic Capital Investigates Clinical Trials & Real World Evidence & Going Mainstream: Mass AdoptionApril Psychedelic Capital Investigates Clinical Trials & Real World Evidence & Going Mainstream: Mass Adoption
finance.yahoo.com - April 28 at 12:58 PM
Short Interest in BetterLife Pharma Inc. (OTCMKTS:BETRF) Declines By 94.8%Short Interest in BetterLife Pharma Inc. (OTCMKTS:BETRF) Declines By 94.8%
americanbankingnews.com - April 28 at 1:00 AM
Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory AdvisorFormer FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory Advisor
finance.yahoo.com - April 8 at 12:27 PM
BetterLife Added to Horizons Psychedelic Stock Index ETFBetterLife Added to Horizons Psychedelic Stock Index ETF
finance.yahoo.com - March 29 at 9:31 AM
BetterLife Pharma says subsidiary Altum Pharmaceuticals to conduct coronavirus trial in Chile using its AP-003BetterLife Pharma says subsidiary Altum Pharmaceuticals to conduct coronavirus trial in Chile using its AP-003
proactiveinvestors.com - March 26 at 8:56 PM
BetterLife Pharma inks research agreement with the University of California San DiegoBetterLife Pharma inks research agreement with the University of California San Diego
proactiveinvestors.com - March 26 at 8:56 PM
BetterLife Pharma: BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology StudiesBetterLife Pharma: BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology Studies
finanznachrichten.de - March 24 at 12:53 PM
BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology StudiesBetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology Studies
finance.yahoo.com - March 24 at 12:53 PM
BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003
finance.yahoo.com - March 11 at 12:21 PM
BetterLife Pharma announces tie-up with Carleton University to study TD-0148A as treatment for depressionBetterLife Pharma announces tie-up with Carleton University to study TD-0148A as treatment for depression
proactiveinvestors.com - March 10 at 8:32 AM
BetterLife Enters Research Agreement with Carleton University for TD-0148A Depression StudiesBetterLife Enters Research Agreement with Carleton University for TD-0148A Depression Studies
finance.yahoo.com - March 8 at 8:09 AM
Proactive news headlines including BetterLife Pharma, HempFusion Wellness, Pure Gold Mining,Proactive news headlines including BetterLife Pharma, HempFusion Wellness, Pure Gold Mining,
apnews.com - March 5 at 12:24 AM
BetterLife engages Eurofins CDMO for psychedelic TD-0148A manufacturingBetterLife engages Eurofins CDMO for psychedelic TD-0148A manufacturing
canadianinvestor.com - March 3 at 7:51 PM
BetterLife Pharma hires Eurofins CDMO to manufacture LSD derivative TD-0148ABetterLife Pharma hires Eurofins CDMO to manufacture LSD derivative TD-0148A
proactiveinvestors.com - March 3 at 2:50 PM
BetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A ManufacturingBetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A Manufacturing
finance.yahoo.com - March 3 at 9:50 AM
BetterLife Pharma files patent protection for its newest compound TD-010 to treat anxiolytic-use disorderBetterLife Pharma files patent protection for its newest compound TD-010 to treat anxiolytic-use disorder
proactiveinvestors.com - February 2 at 12:29 PM
BetterLife Files Patent Protection on Dihydrohonokiol-B for Treatment of Anxiolytic Use DisorderBetterLife Files Patent Protection on Dihydrohonokiol-B for Treatment of Anxiolytic Use Disorder
finance.yahoo.com - February 2 at 12:29 PM
BetterLife Pharma inhaled coronavirus treatment passes six months of cold temperature testsBetterLife Pharma inhaled coronavirus treatment passes six months of cold temperature tests
proactiveinvestors.com - January 28 at 8:16 PM
BetterLife Pharma partners with Eurofins Discovery for pharmacology studies of Eurofins LSD-derived molecule TD-0148ABetterLife Pharma partners with Eurofins Discovery for pharmacology studies of Eurofins' LSD-derived molecule TD-0148A
proactiveinvestors.com - January 28 at 10:15 AM
BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA ...BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA ...
apnews.com - January 28 at 5:15 AM
BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon ...BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon ...
apnews.com - January 26 at 11:23 AM
BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 CasesBetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 Cases
benzinga.com - January 26 at 11:23 AM
DateCompanyBrokerageAction
(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.